卡位黄金赛道!和铂医药联姻蓝纳成,新一代RDC药物研发按下加速键

制药在线
Dec 30, 2025

12月29日,和铂医药与烟台蓝纳成生物技术股份有限公司宣布达成长期战略合作,一起推进新一代放射性核素偶联药物(RDC)的开发。这场合作把和铂医药在全球稀缺的全人源抗体发现平台优势,与蓝纳成在放射性药物研发、生产及商业化方面的专业能力结合起来。眼下RDC领域已经是全球研发与投资的热点,同时也面临不少实际困难,这样的合作模式为中国生物科技企业如何整合资源、打造差异化竞争力、在资本环境趋冷时实现持续发展...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10